Dr. Xia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UCLA Medical Center
Los Angeles, CA 90066- Is this information wrong?
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2022 - 2025
- The University of Texas Health Science Center at San AntonioClass of 2022
- The University of Texas at AustinBS, Biochemistry, Summa cum laude, 2014 - 2018
Certifications & Licensure
- CA State Medical License 2023 - 2025
- American Heart Association ACLS
Awards, Honors, & Recognition
- Award for Excellence in Teaching David Geffen School of Medicine, 2024
- Long Medical Scholar University of Texas Health San Antonio, 2018-2022
- Alpha Omega Alpha University of Texas Health San Antonio, 2021
- Join now to see all
Publications & Presentations
PubMed
- New models for heart failure care delivery.Xia, J., Nicholas K Brownell, Gregg C Fonarow, Boback Ziaeian, Jeffrey Xia> ;Progress in Cardiovascular Diseases. 2024 Feb 2
- 2 citationsSecond-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-maj...Jeffrey Xia, Jonathan Gelfond, Sukeshi Patel Arora> ;Journal of Gastrointestinal Oncology. 2021 Jan 1
- 1 citationsMurine Typhus Presenting as Septic Acute Cholangitis in a Young Woman From South TexasJeffrey Xia, Sabi Shrestha, James C. Saca> ;Cureus. 2021 Nov 2
Abstracts/Posters
- When the way to a man’s heart is through his stomach: Cardiac syncope secondary to massive left hemidiaphragm eventrationJeffrey Xia, Kamran Shamsa, American College of Cardiology, Atlanta, Georgia, 4/6/2024
- Endemic Typhus Masquerading as Septic Ascending CholangitisXia J, Saca J, American College of Physicians Texas Chapter, 11/6/2021
- Second-Line Tyrosine Kinase Inhibitors (TKIs) Versus Immunotherapy (IO) for Advanced Hepatocellular Carcinoma (HCC): Real-World Efficacy and Safety Analysis in Patient...Xia J, Gelfond J, Arora SP, American Society of Clinical Oncologists Gastrointestinal Cancers Symposium, 1/16/2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: